Drug Profile

VS 5584

Alternative Names: SB-2312; SB-2343; VS-5584

Latest Information Update: 11 May 2018

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator S*BIO
Developer Verastem
Class Antineoplastics; Morpholines; Purines; Pyrimidines; Small molecules
Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTORC1 protein inhibitors; MTORC2 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Mesothelioma
New Molecular Entity Yes

Highest Development Phases

Discontinued Lymphoma; Mesothelioma; Solid tumours

Most Recent Events

03 May 2018 Verastem is now operating as Verastem Oncology
23 Mar 2017 Discontinued - Phase-I for Lymphoma (Late-stage disease, Metastatic disease) in USA (PO)
23 Mar 2017 Discontinued - Phase-I for Mesothelioma (Combination therapy, Second-line therapy or greater) in United Kingdom (PO)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com